ArticleLaboratory investigation; a journal of technical methods and pathology2015
Galactose protects hepatocytes against TNF-α-induced apoptosis by promoting activation of the NF-κB signaling pathway in acute liver failure.
Article in Laboratory investigation; a journal of technical methods and pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease.Biomarker research · 2026Review
- Low-dose galactose rebalances HBP-mTORC1-SREBP-1c signaling to suppress hepatic lipogenesis and protect against early-stage alcohol-related liver disease.American journal of physiology. Gastrointestinal and liver physiology · 2026Article
- Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer.Cell death and differentiation · 2025Article
- The serum soluble ASGR1 concentration is elevated in patients with coronary artery disease and is associated with inflammatory markers.Lipids in health and disease · 2024Article
- Correlation between serum soluble ASGR1 concentration and low-density lipoprotein cholesterol levels: a cross-sectional study.Lipids in health and disease · 2023Article
- Non-ammoniagenic proliferation and differentiation media for cultivated adipose tissue.Frontiers in bioengineering and biotechnology · 2023Article
- The dynamics of cell death patterns and regeneration during acute liver injury in mice.FEBS open bio · 2022Article
- Hepatocyte-Conditional Knockout of Phosphatidylethanolamine Binding Protein 4 Aggravated LPS/D-GalN-Induced Acute Liver InjuryFrontiers in immunology · 2022Article
- Ameliorative effect of urolithin A on d-gal-induced liver and kidney damage in aging miceRSC advances · 2020Article
- Mangiferin Attenuates LPS/D-GalN-Induced Acute Liver Injury by Promoting HO-1 in Kupffer Cells.Frontiers in immunology · 2020Article
- Preventive effect of flavonoids from Wushan Shencha (Food science & nutrition · 2019Article
- Phenotypic switch of human and mouse macrophages and resultant effects on apoptosis resistance in hepatocytes.Innate immunity · 2019Article
- Protective role of puerarin on LPS/D-Gal induced acute liver injury via restoring autophagy.American journal of translational research · 2018Article
- TNF-α -308 A allele is associated with an increased risk of distant metastasis in rectal cancer patients from Southwestern China.PloS one · 2017Article
- Impact of Helicobacter pylori on the healing process of the gastric barrier.World journal of gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saccharides are reported to protect hepatocytes from acute liver injury through distinct mechanisms. To date, the protective role of galactose against acute liver injury induced by lipopolysaccharide (LPS) and D-galactosamine (D-GalN) has been attributed to competition with D-GalN. Here, we showed that in addition to its effects on LPS/D-GalN and tumor necrosis factor alpha (TNF-α)/D-GalN models, galactose improves hepatic injury in mice challenged with LPS alone or TNF-α/actinomycin D. Consistent with this result, galactose enhanced the viability of TNF-α-stimulated Chang Liver and Hu7.5 hepatic cell lines. Specifically, galactose prevented TNF-α-induced apoptosis of hepatocytes through promoting phosphorylation of nuclear factor kappa B (NF-κB) p65. Additionally, galactose enhanced expression of the anti-apoptotic genes, c-IAP1 and A20, and inhibited cleavage of caspase-8 and caspase-3. These findings collectively suggest that galactose prevents TNF-α-induced liver injury through activation of the NF-κB signaling pathway. Considering that monosaccharides protect against liver injury via distinct mechanisms, these compounds may represent a promising clinical approach to treat acute liver failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.